Trial Profile

Double-Blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rabeprazole (Primary)
Indications Reflux oesophagitis
Focus Registrational; Therapeutic Use
Acronyms TWICE
Sponsors Eisai Co Ltd

Most Recent Events

20 Mar 2012 Results published in the American Journal of Gastroenterology.
10 May 2011 Results presented at the Digestive Disease Week 2011.
21 Dec 2010 Twice daily administration of 10mg or 20mg doses approved in Japan based on the results of this trial, according to an Eisai Co media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com